title: Compliance with antimicrobial therapy for buruli ulcer.
authors.affiliation: Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands s.klis@umcg.nl.
authors.forename: S
authors.initials: S
authors.lastname: Klis
authors.affiliation: Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Kingma
authors.affiliation: Nkawie-Toase Government Hospital, Nkawie, Ghana.
authors.forename: W
authors.initials: W
authors.lastname: Tuah
authors.affiliation: Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands.
authors.forename: Y
authors.initials: Y
authors.lastname: Stienstra
authors.affiliation: Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: T S
authors.initials: TS
authors.lastname: van der Werf
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D054312:Buruli Ulcer / Q000188:drug therapy*; D017291:Clarithromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019911:Mycobacterium ulcerans / Q000187:drug effects*; D012293:Rifampin / Q000627:therapeutic use*; D013307:Streptomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D017291:Clarithromycin; D012293:Rifampin; D013307:Streptomycin